PE20130375A1 - Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos - Google Patents

Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos

Info

Publication number
PE20130375A1
PE20130375A1 PE2012000903A PE2012000903A PE20130375A1 PE 20130375 A1 PE20130375 A1 PE 20130375A1 PE 2012000903 A PE2012000903 A PE 2012000903A PE 2012000903 A PE2012000903 A PE 2012000903A PE 20130375 A1 PE20130375 A1 PE 20130375A1
Authority
PE
Peru
Prior art keywords
halo
heteroaryl
compounds
triazolopyridines
compositions
Prior art date
Application number
PE2012000903A
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jiang
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130375(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20130375A1 publication Critical patent/PE20130375A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE: (1) X ES N; Y ES O, S, N(R7); R1 ES ARILO Y HETEROARILO OPCIONALMENTE SUSTITUIDO CON HALO, CICLOALQUILO, NO2, ENTRE OTROS; (2) X ES N; Y ESTA AUSENTE; R1 ES HETEROARILO BICICLICO CONDENSADO OPCIONALMENTE SUSTITUIDO CON HALO, CF3, CF2H, ENTRE OTROS; O (3) X ES C(R6); Y ES O, S, N(R7) O PUEDE SER QUE Y ESTE AUSENTE; R1 ES HETEROARILO OPCIONALMENTE SUSTITUIDO CON CN, NO2, ARILO, ENTRE OTROS; R2 Y R3 SON INDEPENDIENTEMENTE H Y ALQUILO, O R2 Y R3 JUNTO CON EL CARBONO AL CUAL ESTAN ENLAZADOS, FORMAN UN ANILLO SELECCIONADO ENTRE CICLOALQUILO DE 3-7 MIEMBROS Y HETEROCICLO DE 3-7 MIEMBROS; R4 ES HALO, ALQUILO, CICLOALQUILO, HETEROCICLO, ARILO Y HETEROARILO SUSTITUIDOS, EXCEPTO EL HALO, CON, ALCOXI, CIANO, ENTRE OTROS; R5 ES H, OH, NH2, CF3, ENTRE OTROS. REFERIDO ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE C-MET, SIENDO UTILES PARA EL TRATAMIENTO DE CANCER
PE2012000903A 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos PE20130375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31

Publications (1)

Publication Number Publication Date
PE20130375A1 true PE20130375A1 (es) 2013-04-10

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2016000292A PE20160588A1 (es) 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE2012000903A PE20130375A1 (es) 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE2020001800A PE20211094A1 (es) 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016000292A PE20160588A1 (es) 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020001800A PE20211094A1 (es) 2009-12-31 2010-12-30 Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos

Country Status (38)

Country Link
US (7) US8987269B2 (es)
EP (5) EP3795573B1 (es)
JP (5) JP5337313B2 (es)
KR (3) KR101905350B1 (es)
CN (3) CN106117248B (es)
AU (2) AU2010338712B2 (es)
BR (1) BR112012016129B1 (es)
CA (1) CA2785749C (es)
CL (1) CL2012001752A1 (es)
CO (1) CO6612235A2 (es)
CU (1) CU24167B1 (es)
CY (2) CY1118250T1 (es)
DK (3) DK3511330T3 (es)
DO (1) DOP2012000188A (es)
EA (2) EA025466B1 (es)
EC (1) ECSP12012011A (es)
ES (4) ES2927146T3 (es)
GT (1) GT201200220A (es)
HK (2) HK1194071A1 (es)
HR (3) HRP20221090T1 (es)
HU (3) HUE052828T2 (es)
IL (2) IL220433B (es)
LT (1) LT3795573T (es)
ME (1) ME02211B (es)
MX (1) MX336996B (es)
MY (1) MY179933A (es)
NI (1) NI201200118A (es)
NZ (1) NZ601128A (es)
PE (3) PE20160588A1 (es)
PL (3) PL3511330T3 (es)
PT (3) PT3795573T (es)
RS (3) RS54217B1 (es)
SG (1) SG181781A1 (es)
SI (2) SI3511330T1 (es)
SM (1) SMT201500213B (es)
UA (1) UA107822C2 (es)
WO (1) WO2011079804A1 (es)
ZA (1) ZA201205730B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3511330T3 (pl) * 2009-12-31 2021-04-19 Hutchison Medipharma Limited Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met
CN107674073B (zh) * 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
KR20140144726A (ko) * 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
RU2655604C2 (ru) 2013-01-11 2018-05-29 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение или его соль
RU2656597C2 (ru) 2013-03-06 2018-06-06 Астразенека Аб Хиназолиновые ингибиторы активирующих мутированных форм рецептора эпидермального фактора роста
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
MX368311B (es) 2013-09-30 2019-09-27 Korea Res Inst Chemical Tech Nuevos derivados de triazolopirazina y usos de los mismos.
MX2016008445A (es) * 2013-12-26 2016-10-28 Ignyta Inc Derivados de pirazolo [1,5-a] piridina y metodos para su uso.
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US10344035B2 (en) * 2015-12-31 2019-07-09 Shanghai Phaarmaceuticals Holding Co., Ltd. Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
ES2933513T3 (es) 2017-03-01 2023-02-09 Achillion Pharmaceuticals Inc Compuestos macrocíclicos para el tratamiento de trastornos médicos
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
JP2022500494A (ja) 2018-09-11 2022-01-04 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag ３−［（１Ｓ）−１−イミダゾ［１，２−ａ］ピリジン−６−イルエチル］−５−（１−メチルピラゾール−４−イル）トリアゾロ［４，５−ｂ］ピラジン及びその多形相の改良製造法
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
CR20210281A (es) * 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
JP2022513215A (ja) 2018-12-14 2022-02-07 ベータ・ファーマ・インコーポレイテッド Ｃ－ｍｅｔ阻害剤としての有機リン置換化合物およびその治療用途
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
EP4107166A1 (en) * 2020-02-20 2022-12-28 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
WO2022066534A1 (en) * 2020-09-28 2022-03-31 Codexis, Inc. Engineered biocatalysts and methods for synthesizing chiral amines
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
WO2022149647A1 (ko) 2021-01-08 2022-07-14 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1643836A4 (en) * 2003-07-02 2006-12-06 Sugen Inc ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINE C-MET INHIBITORS
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006018735A2 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
US7622482B2 (en) * 2005-02-16 2009-11-24 Astrazeneca Chemical compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
MY159523A (en) 2005-12-21 2017-01-13 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
TW200817410A (en) 2006-08-07 2008-04-16 Incyte Corp Triazolotriazines as kinase inhibitors
CA2663528A1 (en) 2006-09-18 2008-03-27 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of c-met and uses thereof
EA200970403A1 (ru) 2006-10-23 2009-10-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Бициклические триазолы в качестве модуляторов протеинкиназы
EA016527B1 (ru) * 2006-10-23 2012-05-30 ЭсДжиЭкс ФАРМАСЬЮТИКАЛЗ, ИНК. Триазолопиридазиновые модуляторы протеинкиназ
MY188338A (en) 2006-11-22 2021-11-30 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
CA2683398A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US8148369B2 (en) 2007-05-10 2012-04-03 Janssen Pharmaceutica Nv Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
CA2717034A1 (en) 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
ATE540038T1 (de) 2008-05-22 2012-01-15 Amgen Inc Heterocyclen als proteinkinaseinhibitoren
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
MX2012001838A (es) * 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
JP5775871B2 (ja) * 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
PL3511330T3 (pl) * 2009-12-31 2021-04-19 Hutchison Medipharma Limited Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met
CN107674073B (zh) 2010-05-17 2021-09-10 印蔻真治疗公司 作为蛋白激酶调节剂的3,5-二取代-3h-咪唑(或[1,2,3]三唑)并[4,5-b] 吡啶化合物

Also Published As

Publication number Publication date
EP3795573A1 (en) 2021-03-24
SI2719699T1 (sl) 2015-12-31
WO2011079804A1 (en) 2011-07-07
US20150368271A1 (en) 2015-12-24
JP2018009004A (ja) 2018-01-18
CU20120101A7 (es) 2012-10-15
US20210154192A1 (en) 2021-05-27
SMT201500213B (it) 2015-10-30
CU24167B1 (es) 2016-03-31
CN106117248A (zh) 2016-11-16
PT3511330T (pt) 2020-12-24
EA025466B1 (ru) 2016-12-30
EA201691461A1 (ru) 2017-01-30
RS54217B1 (en) 2015-12-31
IL239997A0 (en) 2015-08-31
KR101905350B1 (ko) 2018-11-30
EP3795573B1 (en) 2022-07-06
US8987269B2 (en) 2015-03-24
PL2719699T3 (pl) 2016-01-29
ES2726152T3 (es) 2019-10-02
ZA201205730B (en) 2016-01-27
MX2012007756A (es) 2012-11-06
HK1216880A1 (zh) 2016-12-09
CA2785749C (en) 2017-11-28
ES2546635T3 (es) 2015-09-25
JP6647434B2 (ja) 2020-02-14
CY1123777T1 (el) 2022-03-24
HUE059696T2 (hu) 2022-12-28
US10946014B2 (en) 2021-03-16
CN106117248B (zh) 2019-01-22
BR112012016129A2 (pt) 2016-05-31
ECSP12012011A (es) 2012-10-30
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
JP2013516393A (ja) 2013-05-13
US20200179377A1 (en) 2020-06-11
DOP2012000188A (es) 2012-12-31
RS63612B1 (sr) 2022-10-31
KR20170098324A (ko) 2017-08-29
SI3511330T1 (sl) 2021-01-29
EA201200951A1 (ru) 2013-09-30
CY1118250T1 (el) 2017-06-28
EP3511330A1 (en) 2019-07-17
BR112012016129B1 (pt) 2020-11-03
CA2785749A1 (en) 2011-07-07
KR101771299B1 (ko) 2017-08-24
JP5337313B2 (ja) 2013-11-06
DK3511330T3 (da) 2020-12-21
MY179933A (en) 2020-11-19
AU2010338712B2 (en) 2015-04-02
PL3511330T3 (pl) 2021-04-19
CL2012001752A1 (es) 2013-01-25
JP2016155848A (ja) 2016-09-01
JP6486999B2 (ja) 2019-03-20
AU2010338712A1 (en) 2012-07-12
EP3511330B1 (en) 2020-09-30
DK3795573T3 (da) 2022-09-19
HRP20202017T1 (hr) 2021-02-19
NZ601128A (en) 2014-12-24
PE20160588A1 (es) 2016-07-09
IL239997A (en) 2017-11-30
AU2015203480A1 (en) 2015-07-16
JP6194046B2 (ja) 2017-09-06
SG181781A1 (en) 2012-07-30
HRP20150952T1 (hr) 2015-10-09
US20120245178A1 (en) 2012-09-27
CO6612235A2 (es) 2013-02-01
IL220433B (en) 2018-01-31
PT3795573T (pt) 2022-09-15
HRP20221090T1 (hr) 2022-11-25
US8507487B2 (en) 2013-08-13
KR20120125261A (ko) 2012-11-14
HUE025504T2 (en) 2016-02-29
CN102906092B (zh) 2016-08-03
US20170027934A1 (en) 2017-02-02
EP2966075A1 (en) 2016-01-13
HUE052828T2 (hu) 2021-05-28
EP2519524A4 (en) 2013-07-03
MX336996B (es) 2016-02-09
GT201200220A (es) 2014-12-22
JP2013209418A (ja) 2013-10-10
RS61281B1 (sr) 2021-02-26
CN106432225B (zh) 2019-02-19
PT2719699E (pt) 2015-09-30
US9956218B2 (en) 2018-05-01
EP2966075B1 (en) 2019-02-27
HK1194071A1 (en) 2014-10-10
KR101434766B1 (ko) 2014-08-26
PL3795573T3 (pl) 2022-11-21
KR20140059307A (ko) 2014-05-15
EA030141B1 (ru) 2018-06-29
EP2719699A1 (en) 2014-04-16
EP2519524A1 (en) 2012-11-07
ME02211B (me) 2016-02-20
AU2015203480B2 (en) 2017-10-26
EP2719699B1 (en) 2015-07-08
US20120264739A1 (en) 2012-10-18
UA107822C2 (en) 2015-02-25
ES2840454T3 (es) 2021-07-06
CN102906092A (zh) 2013-01-30
US20180263977A1 (en) 2018-09-20
US11896592B2 (en) 2024-02-13
JP2019108345A (ja) 2019-07-04
CN106432225A (zh) 2017-02-22
ES2927146T3 (es) 2022-11-02
LT3795573T (lt) 2022-11-10
DK2719699T3 (en) 2015-08-24
US10512645B2 (en) 2019-12-24

Similar Documents

Publication Publication Date Title
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
ES2515194T3 (es) Derivados de pirrolidina
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
ECSP11010880A (es) Compuestos orgánicos
PE20121159A1 (es) DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
ECSP10010722A (es) Compuestos orgánicos
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
GT200600339A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR060506A1 (es) Compuestos organicos
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
PA8852101A1 (es) Nucleótidos uracil ciclopropílicos
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
DOP2010000022A (es) Derivados de pirimidina 934
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
DOP2011000113A (es) Pirazolilaminopiridinas como inhibidores de fak
CO6260077A2 (es) Pirimidinas biciclicas fusionadas
AR079662A1 (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
AR069436A1 (es) Compuestos de piridina
PE20081368A1 (es) Derivados de azabiciclo[4.1.0]heptano como inhibidores de la recaptacion de serotonina, dopamina y norepinefrina
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica

Legal Events

Date Code Title Description
FC Refusal